explore -WSS

explore

author：fashion 2025-09-28 20:44:28 - browse：12

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Maui wildfire now ranks as the fifth

WSS

Be careful with at

Be careful with at

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

What to know about the judge who will handle the Trump case

Bird flu researchers hone in on Finland’s mink farms

entertainment

explore

knowledge

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Medicare Advantage enrollment hits roughly 33.4 million

Trump demands the U.S. pay no more for drugs than other countries … again

Biden administration begins canceling student loan debt for 804,000 borrowers

Peter Hotez and the public health issue of online harassment

In 'major milestone,' FDA approves first cell therapy for solid tumors

Guidelines to prevent youth baseball injuries need more muscle

YouTube cracks down on misinformation on cancer treatment

Medicare details structure of new drug price negotiation program

In 'major milestone,' FDA approves first cell therapy for solid tumors

hotspot

Novo Nordisk touts Wegovy study, but still struggling with supply

Researchers tackle phage therapy hurdles for wider adoption

A new drug could help frostbite victims avoid its ravages

Patients, digital health players weigh in on FTC's data privacy plan

FDA warns medical device makers about rise in fabricated data

Reporting on presidential health from Reagan to Trump and Biden

hotspot

explore

leisure time

hotspot